José Juan
García Marín
Catedrático de Universidad
Instituto de Investigación Sanitaria Biodonostia
San Sebastián, EspañaInstituto de Investigación Sanitaria Biodonostia-ko ikertzaileekin lankidetzan egindako argitalpenak (8)
2023
-
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480
2022
-
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
-
Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models
Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190
2020
-
Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters
Biochemical Pharmacology, Vol. 171
2016
-
Mechanisms of resistance to chemotherapy in gastric cancer
Anti-Cancer Agents in Medicinal Chemistry, Vol. 16, Núm. 3, pp. 318-334
2014
-
Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases
Gut, Vol. 63, Núm. 10, pp. 1658-1667
-
MicroRNAs and cholestatic liver diseases
Current Opinion in Gastroenterology, Vol. 30, Núm. 3, pp. 303-309
2013
-
Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib
Hepatology, Vol. 58, Núm. 3, pp. 1065-1073